Polyrizon Ltd. recently reported promising outcomes from a pre-clinical study assessing the allergen-blocking capabilities of its PL-14 Allergy Blocker formulation. The study simulated allergen exposure conditions, specifically targeting the ability of PL-14 to prevent allergen penetration through a hydrogel barrier. Notably, the Der p 1 allergen, a significant house dust mite allergen, was tested, revealing that PL-14 effectively limited allergen diffusion over time, showcasing its potential as a nasal barrier against allergens.
Key findings showed that after one hour, only 1.07% of the allergen penetrated the formulation, with minimal increases to 1.14% after two hours and 13.6% after four hours. These results underscore the formulation’s strong barrier properties, particularly during critical early exposure periods when immune responses are likely to be triggered. The allergen load used was significantly higher than typical exposure levels, indicating robust protective capabilities even in extreme conditions.
As the Allergy Immunotherapy market is projected to grow from USD 1.9 billion in 2025 to USD 4.2 billion by 2035, driven by rising allergy prevalence and advancements in treatment methodologies, Polyrizon’s innovative C&C platform positions it favorably within this expanding market. CEO Tomer Izraeli emphasized the potential of PL-14 as a frontline preventive solution for allergic rhinitis. The company is advancing its preclinical development and plans to initiate clinical studies to support regulatory pathways for PL-14 and other candidates.
Polyrizon focuses on developing innovative medical device hydrogels delivered via nasal sprays, which create a barrier against allergens and viruses. Their proprietary Capture and Contain™ hydrogel technology aims to provide a biological mask effect in the nasal cavity, enhancing both bioadhesion and retention for effective drug delivery.
Open the full market picture for your next decision →
